155 related articles for article (PubMed ID: 34915838)
41. Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan.
Yen FS; Wei JC; Yip HT; Hwu CM; Hou MC; Hsu CC
Hepatol Int; 2021 Feb; 15(1):179-190. PubMed ID: 33423239
[TBL] [Abstract][Full Text] [Related]
42. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
43. Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study.
Komamine M; Kajiyama K; Ishiguro C; Uyama Y
Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1166-1174. PubMed ID: 31338935
[TBL] [Abstract][Full Text] [Related]
44. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
Gooßen K; Gräber S
Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
[TBL] [Abstract][Full Text] [Related]
45. Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes.
Wang J; Wu HY; Chien KL
Diabetes Metab; 2022 May; 48(3):101299. PubMed ID: 34728339
[TBL] [Abstract][Full Text] [Related]
46. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure.
Zannad F; Rossignol P
Circulation; 2019 Jan; 139(3):362-365. PubMed ID: 30586788
[No Abstract] [Full Text] [Related]
47. Efficacy and Cardiovascular Safety of DPP-4 Inhibitors.
Subrahmanyan NA; Koshy RM; Jacob K; Pappachan JM
Curr Drug Saf; 2021; 16(2):154-164. PubMed ID: 32819262
[TBL] [Abstract][Full Text] [Related]
48. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis.
Chen M; Liu Y; Jin J; He Q
Ren Fail; 2016; 38(4):581-7. PubMed ID: 26915531
[TBL] [Abstract][Full Text] [Related]
49. Pooled patient level data are better suited than study level data to investigate the link between dipeptidyl peptidase-4 inhibitors and the risk of heart failure in type 2 diabetes.
Patel T; Tesfaldet B; Gandotra C;
BMJ; 2016 May; 353():i2920. PubMed ID: 27220716
[No Abstract] [Full Text] [Related]
50. Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies.
Xu L; Zheng XQ; Liao XX
Prim Care Diabetes; 2022 Feb; 16(1):207-210. PubMed ID: 34953749
[TBL] [Abstract][Full Text] [Related]
51. Outcomes Associated With the Adjunctive Use of Dipeptidyl Peptidase-4 Inhibitors With Insulin Versus Other Antihyperglycemic Medications in Patients With Prediabetes or Diabetes After Cardiac Surgery.
Clark L; Weeda E; Griffin ML; Jones LA; Haney J
J Pharm Pract; 2021 Apr; 34(2):259-264. PubMed ID: 31409190
[TBL] [Abstract][Full Text] [Related]
52. The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism.
Pan X; Xu S; Li J; Tong N
Front Endocrinol (Lausanne); 2020; 11():599355. PubMed ID: 33335511
[TBL] [Abstract][Full Text] [Related]
53. Insight in the safety profile of antidiabetic agents glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors in daily practice from the patient perspective.
van Gorp AM; Rolfes L; Härmark L; van der Horst P; Hendriks J; Vorstenbosch S
Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1588-1595. PubMed ID: 32854158
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus.
Orime K; Terauchi Y
Expert Opin Pharmacother; 2020 Dec; 21(17):2101-2114. PubMed ID: 32990096
[TBL] [Abstract][Full Text] [Related]
55. [The safety of anti-diabetic drugs in heart failure].
Frigy A; Germán-Salló M; Máthé L; Szabó M
Orv Hetil; 2017 Feb; 158(5):163-171. PubMed ID: 28132538
[TBL] [Abstract][Full Text] [Related]
56. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
57. Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study.
Park SH; Jeong HE; Oh IS; Hong SM; Yu SH; Lee CB; Shin JY
Diabetes Obes Metab; 2021 Jun; 23(6):1232-1241. PubMed ID: 33502058
[TBL] [Abstract][Full Text] [Related]
58. The Assessment of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Glucocorticoid-induced Diabetes by Continuous Glucose Monitoring.
Yata Y; Hosojima M; Kabasawa H; Ishikawa T; Kaseda R; Iino N; Suzuki Y; Saito A; Narita I
Intern Med; 2017 Oct; 56(19):2555-2562. PubMed ID: 28883231
[TBL] [Abstract][Full Text] [Related]
59. The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes.
Stoian AP; Sachinidis A; Stoica RA; Nikolic D; Patti AM; Rizvi AA
Metabolism; 2020 Aug; 109():154295. PubMed ID: 32553739
[TBL] [Abstract][Full Text] [Related]
60. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S
PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
